Our HLA-A/B/C and B2M staining results and the associated CTL Target Score calculations suggest that plexiform and nodular benign tumors and MPNST demonstrate similar capacity to present tumoral antigens to CTLs, while diffuse histology tumors may not. The gene discussed is B2M; the disease is benign neoplasm.